[ad_1]
An Eli Lilly & Co. Zepbound injection pen organized within the Brooklyn borough of New York on March 28, 2024.
Shelby Knowles | Bloomberg | Getty Photographs
Eli Lilly on Monday launched a brand new type of its blockbuster weight problems drug, Zepbound, that gives a month’s price of doses in a single pen.
Money-paying sufferers can get the multi-dose gadget, referred to as KwikPen, on the corporate’s direct-to-consumer web site, LillyDirect. Costs begin at $299 monthly for the bottom dose stage.
The pen might function a extra handy possibility for some sufferers, because it reduces the variety of units they’ve to make use of in a month to take the drug. Sufferers can use one pen to take 4 weekly doses of Zepbound.
Presently, sufferers on the remedy use a special single-dose autoinjector gadget every week. Lilly additionally provides single-dose vials of Zepbound, which requires customers to attract the medicine right into a syringe and inject themselves.
The announcement comes as Lilly works to maintain the early success of Zepbound, which has exploded in demand because it first entered the market in late 2023. LillyDirect has been key to Zepbound’s development, and rolling out a brand new type of the drug on the platform might entice much more sufferers.
The torrid development of Zepbound has helped Eli Lilly seize a majority share of the weight-loss drug market from rival Novo Nordisk. Within the firm’s fourth quarter, Zepbound introduced in $4.2 billion in U.S. income, a 122% spike from the earlier yr.
In a launch, Lilly mentioned the Meals and Drug Administration accepted a label growth for Zepbound to incorporate the multi-dose gadget.
The KwikPen is already used for different medication, resembling Lilly’s well-liked diabetes medicine, Mounjaro.
“As a part of our dedication to supporting folks residing with weight problems of their weight administration journey, we’re introducing a brand new possibility with the Zepbound KwikPen, a tool trusted by sufferers globally and in the US for different Lilly medicines,” mentioned Ilya Yuffa, the president of Lilly USA and International Buyer Capabilities, within the launch.
[ad_2]
